Shanghai Junshi Biosciences Co., Ltd. — Capital/Financing Update 2021

Jan 27, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [90 x 33] intentionally omitted <==

SHANGHAI JUNSHI BIOSCIENCES CO., LTD. 上海君實生物醫藥科技股份有限公司*

(a joint stock company incorporated in the People’s Republic of China with limited liability)

(Stock code: 1877)

CLARIFICATION ANNOUNCEMENT IN RESPECT OF MEDIA REPORT

Shanghai Junshi Biosciences Co., Ltd.* (the “ Company ”) noted that certain media reports on 27 January 2021 stated that the Company proposes to issue 9,500,000 new H shares.

The Company wishes to clarify that as of the date of this announcement, it has not been in discussions with any third party, nor has any agreement or arrangement been reached, for allotment or placement of new shares.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board Shanghai Junshi Biosciences Co., Ltd. Mr. Xiong Jun* Chairman

Shanghai, the PRC, 27 January 2021

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing and Dr. Yao Sheng as executive Directors; Dr. Wu Hai, Mr. Tang Yi, Mr. Li Cong, Mr. Yi Qingqing and Mr. Lin Lijun as non-executive Directors; and Dr. Chen Lieping, Mr. Qian Zhi, Mr. Zhang Chun, Dr. Jiang Hualiang and Dr. Roy Steven Herbst as independent non-executive Directors.

• For identification purpose only